|
Aug 3
|
Despite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 years
|
|
Aug 1
|
Syndax: Q2 Earnings Snapshot
|
|
Aug 1
|
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
|
|
Aug 1
|
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
|
|
Jul 29
|
FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
|
|
Jul 29
|
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
|
|
Jul 25
|
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
|
|
Jul 25
|
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
|
|
Jan 9
|
Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets.
|
|
Jan 2
|
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
|
|
Dec 23
|
With 85% ownership of the shares, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is heavily dominated by institutional owners
|
|
Dec 19
|
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 10
|
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
|
|
Dec 5
|
12 Most Promising Stocks to Buy According to Hedge Funds
|
|
Dec 4
|
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
|
|
Oct 2
|
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
|
|
Sep 29
|
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
|
|
Sep 27
|
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Can Afford To Drive Business Growth
|
|
Aug 4
|
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|